Skip to content
About
Management
Board of Directors
Scientific Advisory Board
Therapeutic Areas
Pipeline
OLX07010 in Rare Tauopathies
OLX07010 Alzheimer’s
Technology
MOA
Patents
News & Publications
Partners and Collaborators
Contact Us
Menu
Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010
Home
>
News
>
Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010
Print
Oligomerix
>
News
>
Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010
Oligomerix Announces First-in-Human Dosing of Tau Self-Association Inhibitor OLX-07010
Post navigation
Previous Post
Oligomerix Announces Issuance of Key U.S. Patent for Lead Tau-Targeting Candidate OLX-07010 to Treat Neurodegenerative Diseases
Next Post
Oligomerix Publishes Preclinical Data on Novel Small Molecule Therapeutic in Development for Alzheimer’s Disease and Rare Neurodegenerative Diseases
Ellen Leventry
View posts by Ellen Leventry
Scroll to top
close ×
